Prescription home intravaginal NMES + EMG-biofeedback device for stress urinary incontinence, coded to E0740 and RTM — business case

Intended use: The device is indicated for the treatment of stress urinary incontinence in cognitively intact adult women in the home setting, by prescription, following a documented failed four-week trial of pelvic muscle exercise training.

Rebuilt 2026-10-01 for pivot P2 the discriminating trigger, from the candidate file read cold. The P1 commercially-insured first build is retired, not patched. It had seen none of claims 167–214. P2 the discriminating trigger changed mechanism:. The device now has a two-channel trigger: pelvic floor surface EMG (electromyography) from the probe, plus an abdominal surface-EMG reference from a skin electrode the woman places herself each session. A burst fires on a voluntary pelvic floor contraction and is withheld when the detector sees a Valsalva manoeuvre or abdominal brace before the burst. intended_use:, the payer route and the E0740 (a HCPCS code for durable medical equipment) rental shape are unchanged. At Legal & IP (intellectual property)'s request, the withhold logic is described on this page no further than that field describes it.

Three facts set the shape of the money at P2 the discriminating trigger. Read them before anything else.

1. The closed loop is not new, and the premise that it was is refuted. A prescription EMG-triggered intravaginal stimulator for incontinence is listed and offered for sale in the US: the MyOnyx (K201014 (an FDA 510(k) clearance number)) claim 167refuted. Two cleared KPI devices carry an EMG-triggered mode through a vaginal probe claim 153verified, claim 154verified. A third, an OTC device, is cleared for home use claim 191refuted. P2 the discriminating trigger exists because of this. What P2 the discriminating trigger adds over these devices is a premise nobody has checked: that none of them uses a reference channel to decide when to fire claim 173unconfirmed.
2. The payer does not pay for the differentiator. Any device coded to E0740 gets the same monthly capped-rental allowed amount, and a reference channel cannot raise it claim 193verified. P2 the discriminating trigger earns more than a single-channel device only by winning a larger share of the women dispensed a device. That depends on a prescriber choosing it claim 174unconfirmed and a supplier stocking it claim 170unconfirmed.
3. P2 the discriminating trigger adds a cost line. The reference electrode is used up every session claim 183unconfirmed, and the supplier may have to absorb its cost inside the same monthly amount claim 181unconfirmed.

So at a fixed payer price, P2 the discriminating trigger raises the cost and its only upside is share. This page describes that bet. It does not weigh it.

Who pays

The budget-holder chain, end to end. The manufacturer does not bill a payer. A DME (durable medical equipment) supplier does.

• Writes the cheque:
  • The payer pays the DME supplier. Medicare pays one capped-rental line per month under E0740, with no purchase line. Title passes to the woman after thirteen continuous rental months claim 82verified.
  • Medicare Advantage (Medicare Advantage) plans must cover what NCD 230.8 (a Medicare national coverage determination number) covers claim 137verified.
  • Commercial plans. It is not established that a commercial plan pays a home-dispensed device under its DME benefit claim 123unconfirmed, or that it pays as a rental claim 135unconfirmed.
  • The woman pays coinsurance out of the allowed amount, because the fee schedule figure is an allowed amount and not a payment claim 193verified.
  • The manufacturer is paid by the supplier, at a wholesale price no file states claim 122unconfirmed. That may happen when the supplier buys units into its rental fleet claim 128unconfirmed, or it may split by object: the probe once per woman, the controller once per fleet slot claim 132unconfirmed.
• Out of which budget line:
  • On the payer side: Medicare Part B (Medicare Part B) DME, an MA (Medicare Advantage) plan's DME benefit, or a commercial DME benefit.
  • On the supplier side: rental-fleet inventory, recovered month by month from the payer.
  • No practice budget is touched on the home route. The device carries no practice-expense line claim 69verified.
• Against which comparator:
  • The payer's comparator is any other E0740 rental, at the same amount claim 193verified.
  • The prescriber's comparators are cleared single-channel EMG-triggered devices:
    • K243079, a prescription device labelled for home use claim 153verified;
    • the MyOnyx, sold in the US on prescription claim 167refuted;
    • an OTC home ETS (electrical tissue stimulation) device, K220161 claim 191refuted.
  • Beyond those: open-loop KPI stimulators; in-clinic biofeedback, whose payment attaches to a practitioner service rather than a home device claim 66unconfirmed; and pelvic floor exercise alone.
  • The one triggered incumbent shown with a US price sells as a purchased system claim 194unconfirmed. That is a different buyer, using a different budget, from a home rental.
• Stops buying instead:
  • For the payer, nothing. One E0740 rental month replaces another at the same allowed amount claim 193verified.
  • For the supplier: a unit of whatever it stocks today claim 170unconfirmed.
  • For the practice: possibly in-clinic sessions. Whether that costs the practice net revenue is unestablished claim 68unconfirmed.
  • For the payer, the spend is additive only if the device brings in women who would otherwise not be dispensed anything. No claim speaks to that.

Reimbursement path

Six questions, each with its own evidence position and one basis. No score, no tier and no composite. Read the coverage line first.

Pillars on verified claims: 3/6 · on assumptions: 1 · queued as research: 0

The other two pillars rest on unconfirmed claims: 2a on a PDAC determination, and 2f on a clinical guideline that is not a payment source.

The three verified pillars describe the class and the payment mechanics. The two that decide whether this product is paid for at a margin are 2a and 2b: does it code to E0740, and does the monthly amount clear its cost. Neither rests on a verified claim. P2 the discriminating trigger widened both. 2a now has a second electrode for the PDAC to rule on, and 2b now has a per-session consumable.

What sits behind each row:

• 2a.
  • E0740's descriptor matches the class claim 7verified.
  • Contractor guidance says the code is meant for stimulators with integrated monitoring claim 45unconfirmed.
  • A re-review of every listed E0740 product has been announced claim 73unconfirmed.
  • No manufacturer has listed a closed-loop EMG-gated stimulator under E0740 claim 129unconfirmed.
  • No Level II code or modifier distinguishes a reference-channel trigger claim 182unconfirmed.
  • The E1399 branch of 2a is the only branch on which P2 the discriminating trigger could carry a different Medicare price, because it is individually priced claim 180unconfirmed.
• 2b.
  • The rate: $74.52 per rental month non-rural, July 2026, the same for any device coded E0740 claim 193verified. Puerto Rico is $89.44 claim 71verified. The realized 2024 average allowed was $57.89 per rental month claim 71verified.
  • The cost side is unstated. The file states no build volume claim 120unconfirmed, no sessions per course and no electrodes per session claim 183unconfirmed.
  • Two or three electrodes per session claim 208unconfirmed. A4595 (a HCPCS code for a supply) exists and is priced at $11.40–$13.24, but whether it is separately payable with an E0740 rental is unestablished claim 181unconfirmed.
  • The per-unit cost-of-goods comparison claim 48unconfirmed is written in a unit that does not meet a monthly rental figure claim 112unconfirmed.
• 2c. A practice-expense question arises only if the device moves into the office (Route C).
• 2d.
  • About six rental months per beneficiary in the 2024 book claim 82verified.
  • Services exceed beneficiaries because the code is rental-flagged claim 72verified.
  • Home use of biofeedback therapy is not covered claim 58verified. Whether this device's app-based EMG feedback counts as "biofeedback therapy" under that policy is a judgement nobody has made.
• 2e.
  • MA plans must follow the NCD (national coverage determination) claim 137verified.
  • Aetna CPB 0223 covers stress, urgency or mixed incontinence with no prior-exercise requirement claim 74verified.
  • Cigna's current position is not established by its policy 0160 claim 76verified.
  • Whether any further commercial policy covers the class is open claim 56unconfirmed.
  • Coverage of the class reaches this device as billed only if 2a resolves claim 55unconfirmed.

Three distinctions kept apart deliberately:

• A code existing is not payment, and payment is not coverage. At class level the file has all three: 2a's code claim 7verified, 2b's rate claim 193verified and 2e's policy claim 9verified. For the P2 the discriminating trigger configuration it has none of them claim 180unconfirmed.
• A packaged code pays the facility nothing extra. That does not bite here, because no facility claim exists. The analogous exposure is that the payer pays the same monthly amount whatever the device costs. A feature that adds cost is paid nothing extra claim 193verified.
• 2f is a permanent unconfirmed. An ex-US leg would start this section over.

Verdicts recorded where a check was run this pass:

• python3 -m connectors hcpcs E0740 → verified: "Non-implanted pelvic floor electrical stimulator, complete system", the descriptor claim 7verified records.
• python3 -m connectors payment E0740 --modifier RR → verified, the July 2026 RR capped-rental line claim 193verified records. --state PR → verified at the Puerto Rico amount claim 71verified.
• python3 -m connectors coverage E0740 --expect-stance covered → refuted: "No NCD or LCD in the cached coverage file names E0740 … NOT the same as a denial". The cached index does not link the NCD to the code. That is a gap in the cache, not in what the NCD covers claim 9verified.
• python3 -m connectors ncd 230.8 --expect "failed a documented trial of pelvic muscle exercise" → verified, CMS (Centers for Medicare & Medicaid Services) Pub. 100-3 Rev. 13808 claim 9verified.
• python3 -m connectors rvu E0740 → refuted: "No code E0740 in the cached CMS Physician Fee Schedule RVU file". That is what claim 69verified needs, not evidence against it.
• python3 -m connectors rvu 90912 --device-cost 74.52 → refuted, a practice-expense shortfall. Read it as a unit mismatch on the home route: the stated cost is one month's rental fee, and the in-office service it tests is one this route does not bill into claim 66unconfirmed. It binds only on Route C, and there the device cost is unstated claim 120unconfirmed.
• python3 -m connectors hcpcs E0746 → verified ("Electromyography (emg), biofeedback device"). payment E0746 → refuted: no row on the DMEPOS fee schedule. This is the coding branch in which the reference channel is split out and paid nothing claim 180unconfirmed.
• python3 -m connectors hcpcs A4595 / payment A4595 → verified, a priced monthly supply code. Whether it is separately payable alongside an E0740 rental is a DME MAC (durable medical equipment Medicare administrative contractor) question claim 181unconfirmed.
• python3 -m connectors drg and apc → unconfirmed, no local cache. That is a tooling gap, and it does not matter here because nothing on the home route is facility-billed claim 82verified.
• python3 -m connectors cpt 98977 → unverifiable: "CPT descriptors are AMA-licensed and cannot be scraped or reproduced verbatim … The code NUMBER is not barred". No descriptor is reproduced on this page. The RTM (remote therapeutic monitoring) device-supply scope reaches no named pelvic indication either way claim 77verified.

The money model

There is no market model for this candidate. knowledge-base/market-models/idea-001.md does not exist, so this section does not build a size. It quotes the legs the file holds and names the ones it does not. Every leg above the Medicare fee-for-service floor rests on an unconfirmed claim, on an assumption, or on nothing at all.

How to read the table:

• The 689 is a floor on one payer's book, not a market. The release excludes MA, commercial, Medicaid, VA and cash-pay. It counts every product billed under E0740, not devices like this one claim 70verified.
• The size the Generator first asserted for E0740 was refuted. The 2024 count was 4,130 against the more than 10,000 it claimed claim 17refuted.
• The size the Generator asserted for the in-clinic comparator was refuted too. The 2024 count for CPT (Current Procedural Terminology) 90912 was 28,093 against the more than 200,000 it claimed claim 16refuted.
• The revenue unit. On a rental-flagged code it is allowed amount per beneficiary per year, not the monthly fee. About $347 in the 2024 book claim 163unconfirmed, against about $174 for a three-month course at the 2024 average claim 121unconfirmed. How long she keeps the device sets revenue per woman, not what the device costs claim 140unconfirmed.
• The P2 the discriminating trigger revenue lever is share. The price is fixed per rental month claim 193verified, so the only line P2 the discriminating trigger can move up is the share row, which is blank claim 46unconfirmed. Share depends on prescriber choice claim 174unconfirmed, supplier stocking claim 170unconfirmed and women finishing the course with the extra electrode claim 210unverified.
• The P2 the discriminating trigger cost lever goes the other way. The system is at least five objects with different lifetimes claim 183unconfirmed. The reference electrode can be bought as a cleared part from at least two unrelated makers, so it carries no supply lock in either direction claim 184verified.
• The $3,645.00 is a vendor-page figure for a clinic purchase claim 194unconfirmed. It must not be compared with $74.52 a month as if the two were one unit claim 82verified.

Verdicts on the two connectors this section is mostly made of:

• python3 -m connectors market "Commercially insured women with stress urinary incontinence dispensed a prescription home pelvic floor stimulator each year outnumber the 689 Medicare fee-for-service E0740 beneficiaries" → unverifiable: "has no free, authoritative, machine-queryable source. Stays unconfirmed permanently unless a human attaches a licensed report". The same proposition is on the claim list claim 67unconfirmed.
• python3 -m connectors adoption "A prescribing urogynecologist chooses a home EMG-triggered stimulator whose trigger uses a self-placed abdominal reference electrode over a cleared single-channel EMG-triggered device" → unverifiable: "needs primary research (interviews, survey, published preference study) … Do NOT substitute a model's own estimate of stakeholder behaviour". That is claim 174unconfirmed, and only primary research settles it.
• python3 -m connectors adoption "A DME supplier stocks a two-channel EMG-triggered home pelvic floor stimulator in its E0740 rental inventory" → unverifiable, the same verdict. That is claim 170unconfirmed.

Path to first revenue

• First dollar comes from: a DME supplier buying units for its E0740 rental fleet, if manufacturer revenue is booked when the supplier acquires units rather than per woman dispensed claim 128unconfirmed. Route C's first dollar comes from a practice instead. Route D's comes from a licensee.
• What must exist first:
  • A 510(k) (premarket notification) under 21 CFR (Title 21 of the Code of Federal Regulations) 876.5320 / KPI at P2 the discriminating trigger. This needs FDA (US Food and Drug Administration) to accept the reference channel as a technological difference that raises no new question claim 188unconfirmed. Equivalence on the trigger itself is FDA's call claim 155unconfirmed.
  • E0740 coding of the P2 the discriminating trigger system claim 180unconfirmed, arriving inside the window and not behind the announced re-review claim 134unconfirmed.
  • A supplier willing to stock it claim 170unconfirmed.
  • A prescriber who chooses it claim 174unconfirmed and teaches the woman to place the electrode claim 212unverified.
  • A woman who can place the electrode herself, unsupervised claim 172unconfirmed.
• Calendar to first dollar: sub-two-year, as asserted for the P1 commercially-insured first shape claim 30unconfirmed. P2 the discriminating trigger's added verification and validation fit inside it [assumption A2 A device with this intended use is eligible…].
• Capital to first dollar: low-single-digit-million, as asserted for the P1 commercially-insured first shape claim 30unconfirmed. P2 the discriminating trigger's added verification and validation fit inside it [assumption A2 A device with this intended use is eligible…].

Routes

Four routes, laid out side by side. This section does not rank them or choose between them. Choosing a commercial strategy is a human's decision. Two things bear on all four, so they are not used as any one route's kill:

• Premise 173. If any cleared incumbent's trigger already withholds on an abdominal channel claim 173unconfirmed, P2 the discriminating trigger has no differentiator to rent, sell or license. That question sits upstream of every route here.
• Freedom to operate. Four live US grants sit on EMG-triggered pelvic floor stimulation claim 21unconfirmed. Their term may run to about 2036 rather than 2040 claim 196unconfirmed. Claim scope has not been read on any of them.

Route A — Home rental through DME suppliers, commercial DME benefit first (P1 commercially-insured first as it stands)

• Requires:
  • The P2 the discriminating trigger 510(k) claim 188unconfirmed.
  • E0740 coding, or its commercial equivalent claim 180unconfirmed.
  • Commercial plans that pay a home-dispensed device under their DME benefit claim 123unconfirmed.
  • Coverage policies like Aetna's, with no prior-exercise requirement claim 74verified, covering a material share of commercially insured women claim 81unconfirmed.
  • Suppliers serving commercial patients through the same channel that bills Medicare claim 90unconfirmed, and willing to stock it claim 170unconfirmed.
• Costs:
  • Clearance and coding inside the envelope claim 30unconfirmed [assumption A2 A device with this intended use is eligible…].
  • A landed monthly cost under the allowable [assumption A1 The classification regulation for a…].
  • Prior-authorization work by the prescribing practice claim 63unconfirmed.
• Killed by: a read of named commercial plans' DME benefit terms finding that a medical-necessity determination for intravaginal stimulation does not produce DME payment for a home-dispensed device claim 123unconfirmed.

Route B — Home rental through DME suppliers, Medicare FFS and Medicare Advantage first (unwinding P1 commercially-insured first)

• Requires:
  • The P2 the discriminating trigger 510(k) claim 188unconfirmed.
  • E0740 coding of the P2 the discriminating trigger system as one system claim 180unconfirmed.
  • Women who meet the NCD's criteria claim 9verified, in MA as well as FFS claim 137verified.
  • Prescribers who document the failed four-week trial claim 29unconfirmed.
  • A supplier among those billing E0740 today willing to stock it claim 170unconfirmed.
• Costs:
  • Clearance and coding inside the envelope claim 30unconfirmed [assumption A2 A device with this intended use is eligible…].
  • A landed monthly cost under the fixed Medicare allowable [assumption A1 The classification regulation for a…] claim 193verified.
  • Supplier enrolment and documentation that a DMEPOS rental carries.
• Killed by: the PDAC coding the P2 the discriminating trigger system as anything other than one E0740 system. Under E0746 the reference channel has no fee schedule amount, and under E1399 it is individually priced. Either takes the route off the national rental line it is built on claim 180unconfirmed.

Route C — Sell the system outright to clinics and practices, against the sold MyOnyx

• Requires:
  • The P2 the discriminating trigger 510(k), possibly with a supervised-use labelling path claim 188unconfirmed.
  • A practice buyer who pays for the reference channel over the one triggered system shown on US sale [assumption A3 Medicare NCD 230.8 covers pelvic floor…] claim 194unconfirmed.
  • A direct-to-practice sales channel claim 53unconfirmed.
  • No PDAC coding and no rental cadence.
• Costs:
  • A sales channel to practices claim 53unconfirmed.
  • In-office use bills a practitioner service, not the device, so the practice carries the purchase claim 66unconfirmed.
  • Home use of biofeedback is not covered, so the route gives up the home DME benefit claim 58verified.
  • Clearance inside the envelope claim 30unconfirmed [assumption A2 A device with this intended use is eligible…].
• Killed by: a pricing read of practice purchasers finding that none would pay more for the reference channel than the MyOnyx bundle's published list price [assumption A3 Medicare NCD 230.8 covers pelvic floor…].

Route D — License the withhold logic to a cleared two-channel ETS holder

• Requires:
  • A holder of K243079 or K201014, whose hardware already carries a second EMG channel claim 202verified, willing to pay for the logic rather than build it [assumption A4 TAM component 1].
  • Something to license. No issued patent claims the withhold claim 198unconfirmed, and no prior publication discloses it claim 199unconfirmed.
  • The licensee files its own new 510(k) for the change claim 213unverified.
• Costs:
  • Patent prosecution and counsel's review of the four live grants claim 21unconfirmed.
  • Little device-build spend. The licensee carries clearance, coding and channel.
  • The licensee's own regulatory spend for the change claim 213unverified.
• Killed by: a publication dated before 2026-10-01 that discloses withholding EMG-triggered pelvic floor stimulation on an abdominal surface-EMG reference channel. That would leave nothing protectable to license. Two Chinese abstracts with pelvic-plus-abdominal surface-EMG channels are unread leads on exactly this claim 199unconfirmed.

Assumption register

All four assumptions cited above, with what would settle each and who could run it. They were written back to the candidate as claims 215–218 before this file was written. Each falsifier is written to run off a registry, a document or a revealed behaviour where it can. A falsifier that runs through a prescribing practice depends on that practice letting a manufacturer in, which is itself unestablished claim 126unconfirmed.

Older assumptions are not repeated. The retired builds' assumptions are claims 46–54, 66–69, 121–123 and 132–137, and this page cites them at their current tags.

Where this case outruns the file

Every figure this case needs that no verified claim carries. These are the work items.

• A market model. None exists. /market-model idea-001 (REQ-0046 Build the market model this candidate has…) is the only pass in the repo that would type the size legs and commission the missing ones. Under P2 the discriminating trigger, its units leg has to count five objects, not one.
• Commercially insured units per year. Only an unconfirmed comparative claim speaks to it. market returns unverifiable on it, permanently.
• Medicare Advantage volume on E0740. The duty to cover is verified. The number is not measured.
• Share won by a P2 the discriminating trigger device. This is the only revenue line P2 the discriminating trigger can move. It is blank.
• Manufacturer price to the supplier, and whether it can cover per-session electrodes at a fixed allowable.
• Landed cost per rental month (A1 The classification regulation for a…). It needs a bill of materials, sessions per course, electrodes per session and a controller service life, and the file states none of them.
• Gross margin. It cannot be stated until the two lines above exist.
• Calendar and capital to first revenue at P2 the discriminating trigger (A2 A device with this intended use is eligible…). The envelope on file was asserted for P1 commercially-insured first and was never costed.
• Practice willingness to pay for the reference channel (A3 Medicare NCD 230.8 covers pelvic floor…), and an incumbent's willingness to license it (A4 TAM component 1).
• Whether the differentiator exists at all claim 173unconfirmed. This sits upstream of every figure above. A labelling read (REQ-0166 Read the manufacturer labelling) settles it more cheaply than anything on this list.